CN105308068A - 高度半乳糖基化的抗TNF-α抗体及其用途 - Google Patents

高度半乳糖基化的抗TNF-α抗体及其用途 Download PDF

Info

Publication number
CN105308068A
CN105308068A CN201480020371.4A CN201480020371A CN105308068A CN 105308068 A CN105308068 A CN 105308068A CN 201480020371 A CN201480020371 A CN 201480020371A CN 105308068 A CN105308068 A CN 105308068A
Authority
CN
China
Prior art keywords
antibody
antibodies
composition
population
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480020371.4A
Other languages
English (en)
Chinese (zh)
Inventor
H.M.米德
L-H.陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB Biotechnologies SAS
Original Assignee
LFB Biotechnologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB Biotechnologies SAS filed Critical LFB Biotechnologies SAS
Publication of CN105308068A publication Critical patent/CN105308068A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39508—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from milk, i.e. lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201480020371.4A 2013-02-13 2014-02-13 高度半乳糖基化的抗TNF-α抗体及其用途 Pending CN105308068A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764475P 2013-02-13 2013-02-13
US61/764,475 2013-02-13
PCT/IB2014/000692 WO2014125374A2 (en) 2013-02-13 2014-02-13 Highly galactosylated anti-tnf-alpha antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN105308068A true CN105308068A (zh) 2016-02-03

Family

ID=50980321

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480020371.4A Pending CN105308068A (zh) 2013-02-13 2014-02-13 高度半乳糖基化的抗TNF-α抗体及其用途

Country Status (14)

Country Link
US (3) US10174110B2 (enExample)
EP (3) EP3594230A1 (enExample)
JP (2) JP2016508515A (enExample)
KR (1) KR20160002713A (enExample)
CN (1) CN105308068A (enExample)
AR (1) AR094780A1 (enExample)
AU (1) AU2014217561B2 (enExample)
BR (1) BR112015019341A2 (enExample)
CA (1) CA2900909A1 (enExample)
ES (1) ES2755181T3 (enExample)
IL (1) IL240443A0 (enExample)
MX (1) MX2015010427A (enExample)
TW (1) TW201506041A (enExample)
WO (1) WO2014125374A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112695039A (zh) * 2013-08-26 2021-04-23 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8164343B2 (en) 2003-09-05 2012-04-24 Midtronics, Inc. Method and apparatus for measuring a parameter of a vehicle electrical system
JP6189751B2 (ja) 2010-12-30 2017-08-30 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 病原体不活性化剤としてのグリコール
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
CN105308071A (zh) * 2013-02-13 2016-02-03 法国化学与生物科技实验室 高度半乳糖基化的抗her2抗体及其用途
JP2016508515A (ja) 2013-02-13 2016-03-22 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
AU2014285971A1 (en) 2013-07-05 2016-02-04 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Affinity chromatography matrix
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
FR3022462B1 (fr) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha
SG11201700446XA (en) 2014-07-21 2017-02-27 Glykos Finland Oy Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
FR3034419B1 (fr) 2015-04-02 2017-12-15 Lab Francais Du Fractionnement Procede de purification d'une proteine recombinante therapeutique a partir d'un lait transgenique
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3257866A1 (en) * 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
FR3054444A1 (fr) 2016-07-29 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnf alpha
EP3581203A1 (en) * 2018-06-11 2019-12-18 Laboratoire Français du Fractionnement et des Biotechnologies Antibodies with increased activity in the digestive tract
CN116903738A (zh) * 2022-08-02 2023-10-20 北京绿竹生物技术股份有限公司 一种低甘露糖型抗人肿瘤坏死因子-α单抗及其用途
EP4630056A2 (en) * 2022-12-09 2025-10-15 Xentria, Inc. Methods of treating sarcoidosis with a tnf-a antibody and associated compositions and methods
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243459C (en) * 1996-02-09 2002-09-17 Basf Aktiengesellschaft Human antibodies that bind human tnf.alpha.
US20040101939A1 (en) * 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
CN1729298A (zh) * 2002-11-27 2006-02-01 Gtc生物治疗学公司 在乳汁中稳定生成的修饰抗体及其制备方法
CA2734139A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
WO2009083246A1 (en) * 2007-12-31 2009-07-09 Bayer Schering Pharma Aktiengesellschaft Antibodies to tnf alpha
CN101484470A (zh) * 2005-10-21 2009-07-15 Gtc生物治疗有限公司 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途
CN101506238A (zh) * 2005-06-30 2009-08-12 森托科尔公司 具有提高治疗活性的方法和成分
CN101588817A (zh) * 2006-09-10 2009-11-25 葛莱高托普有限公司 骨髓白血病来源的细胞在抗体表达中的用途
CN101646775A (zh) * 2006-12-28 2010-02-10 森托科尔奥索生物技术公司 用于产生脱唾液酸化免疫球蛋白的方法和载体

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
GB8615942D0 (en) 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
WO1988001648A1 (en) 1986-08-28 1988-03-10 Immunex Corporation Expression of heterologous proteins by transgenic lactating mammals
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8826446D0 (en) 1988-11-11 1988-12-14 Agricultural & Food Res Peptide production
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP0502976B1 (en) 1989-12-01 1996-07-03 Pharming B.V. Production of recombinant polypeptides by bovine species and transgenic methods
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE4000939A1 (de) 1990-01-15 1991-07-18 Brem Gottfried Prof Dr Dr Verfahren zur antikoerpergewinnung
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
US5648253A (en) 1990-12-20 1997-07-15 Tsi Corporation Inhibitor-resistant urokinase
JPH06507307A (ja) 1991-01-11 1994-08-25 アメリカン・レツド・クロス トランスジェニック動物の乳腺組織における活性ヒトプロテインｃの発現
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5831141A (en) 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
EP0597010A4 (en) 1991-07-31 1996-12-27 Rhone Poulenc Rorer Int Transgenic protein production.
US6448469B1 (en) 1991-10-02 2002-09-10 Genzyme Corporation Production of membrane proteins in the milk of transgenic nonhuman mammals
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5639940A (en) 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
WO1995024488A1 (en) 1994-03-09 1995-09-14 Abbott Laboratories Transgenic animals producing oligosaccharides and glycoconjugates
US5750176A (en) 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
AU694181B2 (en) 1994-03-09 1998-07-16 Abbott Laboratories Humanized milk
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5780009A (en) 1995-01-20 1998-07-14 Nexia Biotechnologies, Inc. Direct gene transfer into the ruminant mammary gland
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
EP0849275A1 (en) 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylated peptides
AU4984697A (en) 1996-10-11 1998-05-11 The Texas A & M University System Methods for the generation of primordial germ cells and transgenic animal species
US6063905A (en) 1997-01-07 2000-05-16 Board Of Regents, The University Of Texas System Recombinant human IGA-J. chain dimer
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US6528699B1 (en) 1997-02-25 2003-03-04 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
EP0977837A1 (en) 1997-04-03 2000-02-09 Universite Laval Transgenic expression in genital tract and sexual accessory glands
AU738888B2 (en) 1997-05-29 2001-09-27 Agresearch Limited Processes for production of immunoglobulin A in milk
US6210736B1 (en) 1997-06-17 2001-04-03 Genzyme Transgenics Corporation Transgenically produced prolactin
BR9812945A (pt) 1997-10-20 2000-08-08 Genzyme Transgenics Corp Sequências de ácido nucléico modificadas e processos para aumentar os nìveis de mrna e expressão de sistemas celulares
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
AU775422B2 (en) 1998-06-15 2004-07-29 Gtc Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion
US20030005468A1 (en) 1998-06-19 2003-01-02 Meade Harry M. Methods and vectors for improving nucleic acid expression
US20040117863A1 (en) 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
US20030177513A1 (en) 1998-11-02 2003-09-18 Yann Echelard Transgenic and cloned mammals
US6580017B1 (en) 1998-11-02 2003-06-17 Genzyme Transgenics Corporation Methods of reconstructed goat embryo transfer
EP1818397A1 (en) 1998-11-02 2007-08-15 Trustees Of Tufts College Methods for cloning animals
WO2000030436A1 (en) 1998-11-19 2000-06-02 Ppl Therapeutics (Scotland) Ltd. Stabilisation of milk from transgenic animals
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
CA2362565A1 (en) 1999-02-22 2000-08-31 Eric F. Bernstein Compositions and methods for prevention of photoaging
EP1194570A1 (en) 1999-06-23 2002-04-10 PPL Therapeutics (Scotland) Limited Fusion proteins incorporating lysozyme
KR100772465B1 (ko) 1999-10-14 2007-11-02 지티씨바이오쎄라퓨틱스,인크. 트랜스제닉 동물 내에서 표적 분자를 생성시키는 방법, 및그 표적 분자를 정제하는 방법
US7414170B2 (en) 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
CA2399561A1 (en) 2000-02-03 2001-08-09 Lennart Hammarstrom Ruminant mhc class i-like fc receptors
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
KR20030060772A (ko) 2000-05-05 2003-07-16 지티씨바이오쎄라퓨틱스,인크. 형질전환법으로 생성된 데코린
BR0111817A (pt) 2000-06-19 2003-08-05 Gtc Biotherapeutics Inc Fator de crescimento derivado de plaquetas transgenicamente produzido
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US6924412B1 (en) 2000-07-21 2005-08-02 Arriwan Holding B.V. Means and methods for raising antibody concentration in compartments of the body of a non-human animal
WO2002012441A2 (en) 2000-08-10 2002-02-14 Genzyme Transgenics Corporation Cryopreservation of sperm
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk PROCESS FOR PURIFYING ANTIBODY
US20040226052A1 (en) 2000-10-13 2004-11-11 Meade Harry M. Methods of producing a target molecule in a transgenic animal and purification of the target molecule
EP2325205A3 (en) 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
NZ529767A (en) 2001-06-13 2005-10-28 Taurus Hsa Llc Purification of human serum albumin
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DE60232895D1 (de) 2001-10-09 2009-08-20 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
JP2005515782A (ja) 2002-01-11 2005-06-02 ジーティーシー バイオセラピューティックス インコーポレイテッド 再構築された胚へ核を移植した後の融合および活性化のための方法およびシステム
US20040133931A1 (en) 2003-01-08 2004-07-08 Gavin William G. Method and system for fusion and activation following nuclear transfer in reconstructed embryos
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
KR20040105838A (ko) 2002-04-01 2004-12-16 지티씨바이오쎄라퓨틱스,인크. 폐 질환의 치료 방법
NZ535367A (en) 2002-04-01 2008-01-31 Gtc Biotherapeutics Inc A method for selecting cell lines to be used for nuclear transfer in mammalian species
NZ538216A (en) 2002-07-15 2008-09-26 Mayo Foundation Treatment and prophylaxis with 4-1BB-binding agents
EP1534065A4 (en) 2002-08-01 2005-11-09 Gtc Biotherapeutics Inc PROCESS FOR THE SELECTION OF CELLS FOR CELL CORE TRANSFER IN SOMATIC CELLS
JP2006508062A (ja) 2002-09-17 2006-03-09 ジーティーシー バイオセラピューティックス インコーポレイテッド 重鎖間ジスルフィド結合を欠く免疫グロブリン分子の単離
AU2003295584A1 (en) 2002-11-18 2004-06-15 Taurus Hsa Llc Method for continuous, automated blending of solutions from acids and bases
US7087719B2 (en) 2002-11-19 2006-08-08 Gtc Biotherapeutics, Inc. Method for the crystallization of human serum albumin
EP1578192A4 (en) 2002-12-10 2006-03-29 Gtc Biotherapeutics Inc METHOD AND SYSTEM FOR USING APPROPRIATED CORE TRANSFEREMBRYOES AS CELL DISPENSERS FOR AN ADDITIONAL NUCLEAR TRANSFER
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
JP2006515227A (ja) 2003-02-24 2006-05-25 ジーティーシー バイオセラピューティックス インコーポレイテッド 十字流濾過の方法およびそのための装置
EP2502935B1 (en) 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
CA2537273A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
CN1852977A (zh) 2003-09-15 2006-10-25 Gtc生物治疗学公司 显性失活的跨膜受体在转基因动物乳汁中的表达
FR2861080B1 (fr) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
US20050169908A1 (en) 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050186608A1 (en) 2004-02-19 2005-08-25 Olsen Byron V. Method for the production of transgenic proteins useful in the treatment of obesity and diabetes
US20050192226A1 (en) 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050197496A1 (en) 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
US7667089B2 (en) 2004-04-09 2010-02-23 National Chung Hsing University Transgenic mammal secreting B-domain deleted human FVII in its milk
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20050245444A1 (en) 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
EP1771477A2 (en) 2004-07-21 2007-04-11 Glycofi, Inc. Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform
US20080107601A1 (en) 2004-10-13 2008-05-08 Ablynx N.V. Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
US20060121004A1 (en) 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US20060123500A1 (en) 2004-12-07 2006-06-08 Gtc Biotherapeutics, Inc. Methods of prescreening cells for nuclear transfer procedures
US20060130159A1 (en) 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
US20060168671A1 (en) 2005-01-21 2006-07-27 Gavin William G Injection of caprine sperm factor (cSF), phospholipase C zeta (PLCzeta) and adenophostin A as alternative methods of activation during nuclear transfer in the caprine species
WO2006088447A1 (en) 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
WO2006088464A2 (en) 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20080019905A9 (en) 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20060182744A1 (en) 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
US20060286548A1 (en) 2005-06-16 2006-12-21 Gregory Liposky Method of making recombinant human antibodies for use in biosensor technology
KR20080031024A (ko) * 2005-07-21 2008-04-07 아보트 러보러터리즈 폴리단백질, 프로단백질 및 단백질분해를 사용한 ｓＯＲＦ작제물 포함 다중 유전자 발현 및 방법
WO2007014244A2 (en) 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
EP1937305A4 (en) 2005-09-09 2008-10-08 Glycofi Inc IMMUNOGLOBULIN CONTAINING PRESENTLY A MAN7GLCNAC2, MAN8GLCNAC2 GLYCOFORM
ES2376083T3 (es) 2005-10-21 2012-03-08 Genzyme Corporation Terapéuticos basados en anticuerpos con actividad adcc mejorada.
EP2377886A1 (en) 2005-12-12 2011-10-19 F. Hoffmann-La Roche AG Antibody glycosylation in the variable region
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CN101460522B (zh) 2006-04-11 2014-07-23 弗·哈夫曼-拉罗切有限公司 糖基化抗体
US8173860B2 (en) 2006-04-21 2012-05-08 Gtc Biotherapeutics, Inc. Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
US20100173323A1 (en) 2006-06-09 2010-07-08 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
FR2904558B1 (fr) 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
ES2620261T3 (es) 2006-09-10 2017-06-28 Glycotope Gmbh Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
US20100247570A1 (en) 2006-11-13 2010-09-30 Procell Corporation High Mannose Glycoprotein Epitopes
US8450068B2 (en) 2007-02-16 2013-05-28 University Of Virginia Patent Foundation IgE antibodies to chimeric or humanized IgG therapeutic monoclonal antibodies as a screening test for anaphylaxis
EP1985633A1 (en) 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases
ES2415604T3 (es) 2007-05-30 2013-07-26 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
CN101802210A (zh) 2007-06-13 2010-08-11 斯特林贝尔德生物技术北美公司 在奶中产生外源蛋白的转基因哺乳动物
EP2230900A4 (en) 2008-01-07 2013-01-09 Synageva Biopharma Corp GLYCOSYLATION IN BIRDS
US20110229460A1 (en) 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
JP2012503656A (ja) 2008-09-26 2012-02-09 エウレカ セラピューティクス，インコーポレイテッド 変異体グリコシル化パターンを有する細胞株およびタンパク質
US20100178292A1 (en) 2009-01-12 2010-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cryptic glycan markers and applications thereof
US20110082083A1 (en) 2009-04-10 2011-04-07 Gtc Biotherapeutics, Inc. Formulations of liquid stable antithrombin
AR076796A1 (es) * 2009-05-28 2011-07-06 Glaxo Group Ltd Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento.
JP6189751B2 (ja) 2010-12-30 2017-08-30 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 病原体不活性化剤としてのグリコール
WO2012105699A1 (ja) * 2011-02-03 2012-08-09 株式会社イーベック 補体依存性生物活性の高い抗体の産生法
US20140242182A1 (en) 2011-07-07 2014-08-28 rEVO Biologics, Inc Formulations that stabilize proteins
JP6433786B2 (ja) 2011-08-10 2018-12-05 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高度ガラクトシル化抗体
EP2753634B1 (en) 2011-08-17 2017-11-01 Ares Trading S.A. Method for preparing active form of tnfr-fc fusion protein
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
CN104302312A (zh) 2011-12-19 2015-01-21 Lfb美国股份有限公司 用于炎性病症治疗的重组人α-1-抗胰蛋白酶
TW201400499A (zh) 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
US20150175678A1 (en) 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
CA2879763C (en) 2012-08-03 2020-12-01 Simon LOWRY The use of antithrombin in extracorporeal membrane oxygenation
US20160039913A1 (en) 2012-09-10 2016-02-11 Lfb Usa, Inc. The use of antibodies in treating hiv infection and suppressing hiv transmission
JP2016508515A (ja) 2013-02-13 2016-03-22 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用
CA2900915A1 (en) 2013-02-13 2014-08-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Cetuximab with modified glycosylation and uses thereof
CN105308071A (zh) 2013-02-13 2016-02-03 法国化学与生物科技实验室 高度半乳糖基化的抗her2抗体及其用途
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
FR3005576B1 (fr) 2013-05-15 2015-06-19 Lab Francais Du Fractionnement Procede d'inactivation d'une proteine prion
AU2014285971A1 (en) 2013-07-05 2016-02-04 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Affinity chromatography matrix
FR3015484A1 (fr) 2013-12-20 2015-06-26 Lab Francais Du Fractionnement Proteines recombinantes possedant une activite de facteur h
CN105828603A (zh) 2013-12-24 2016-08-03 Lfb美国股份有限公司 肝素的转基因生产
AU2015270152A1 (en) 2014-06-02 2016-12-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of Fc fragments
FR3022462B1 (fr) 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha
US20160158676A1 (en) 2014-12-01 2016-06-09 Laboratoire Français Du Fractionnement Et Des Biotechnologies Method and apparatus for manipulating components of a filtration system

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243459C (en) * 1996-02-09 2002-09-17 Basf Aktiengesellschaft Human antibodies that bind human tnf.alpha.
US20040101939A1 (en) * 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
CN1729298A (zh) * 2002-11-27 2006-02-01 Gtc生物治疗学公司 在乳汁中稳定生成的修饰抗体及其制备方法
CN101506238A (zh) * 2005-06-30 2009-08-12 森托科尔公司 具有提高治疗活性的方法和成分
CN101484470A (zh) * 2005-10-21 2009-07-15 Gtc生物治疗有限公司 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途
CN101588817A (zh) * 2006-09-10 2009-11-25 葛莱高托普有限公司 骨髓白血病来源的细胞在抗体表达中的用途
CN101646775A (zh) * 2006-12-28 2010-02-10 森托科尔奥索生物技术公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
CA2734139A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
WO2009083246A1 (en) * 2007-12-31 2009-07-09 Bayer Schering Pharma Aktiengesellschaft Antibodies to tnf alpha

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112695039A (zh) * 2013-08-26 2021-04-23 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸
CN112695039B (zh) * 2013-08-26 2025-07-29 生物技术研发公司 编码抗唾液酸化路易斯a抗原的人抗体的核酸

Also Published As

Publication number Publication date
US10174110B2 (en) 2019-01-08
BR112015019341A2 (pt) 2017-08-22
JP2016508515A (ja) 2016-03-22
MX2015010427A (es) 2016-03-17
AU2014217561B2 (en) 2018-11-15
IL240443A0 (en) 2015-09-24
EP3594231A1 (en) 2020-01-15
ES2755181T3 (es) 2020-04-21
EP2956480B1 (en) 2019-09-04
US20190309057A1 (en) 2019-10-10
US20150368334A1 (en) 2015-12-24
JP2020073550A (ja) 2020-05-14
EP2956480A2 (en) 2015-12-23
KR20160002713A (ko) 2016-01-08
WO2014125374A3 (en) 2014-12-31
AU2014217561A1 (en) 2015-08-27
EP3594230A1 (en) 2020-01-15
WO2014125374A2 (en) 2014-08-21
CA2900909A1 (en) 2014-08-21
US20190309058A1 (en) 2019-10-10
TW201506041A (zh) 2015-02-16
AR094780A1 (es) 2015-08-26

Similar Documents

Publication Publication Date Title
US10174110B2 (en) Highly galactosylated anti-TNF-α antibodies and uses thereof
RU2466189C2 (ru) ВЕКТОР ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДОВ С СИАЛИДАЗНОЙ АКТИВНОСТЬЮ, СПОСОБ ОБЕСПЕЧЕНИЯ СИАЛИДАЗНОЙ АКТИВНОСТИ В КУЛЬТУРЕ КЛЕТОК И СПОСОБ РЕГУЛИРОВАНИЯ СВОЙСТВ Fc-СОДЕРЖАЩИХ МОЛЕКУЛ, ЭКСПРЕССИРУЕМЫХ В ЛИНИИ КЛЕТОК
JP2020125286A (ja) 高ガラクトシル化抗ｈｅｒ２抗体およびその使用
EP2956484B1 (en) Cetuximab with modified glycosylation and uses thereof
JP2009504569A (ja) 向上した治療活性をもつ方法および組成物
AU2025230675A1 (en) Variants with Fc fragment having an increased affinity for FcRn and an increased affinity for at least one receptor of the Fc fragment
US20170129966A1 (en) Production of fc fragments
CN116710482A (zh) 特异性结合4-1bb的抗体及其抗原结合片段
CN120112549A (zh) 具有增强的效应子功能的糖基工程化Fc变体多肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160203

WD01 Invention patent application deemed withdrawn after publication